Regeneron Partners with Mammoth for CRISPR Gene Editing Pursuits

loading Regeneron Partners with Mammoth for CRISPR Gene Editing Pursuits

Regeneron Pharmaceuticals and Mammoth Biosciences have entered into a strategic collaboration to advance gene editing therapies using CRISPR technology. This partnership combines Mammoth's CRISPR-based gene editing platform with Regeneron's proprietary delivery technologies, aiming to develop treatments for a variety of diseases with a focus on reaching tissues beyond the liver.

Under the terms of the agreement, Mammoth will receive a $100 million upfront payment from Regeneron, which includes a $95 million equity investment and a $5 million cash payment. Additionally, Mammoth is eligible to receive up to $370 million per therapy in potential future development, regulatory, and commercial milestones. The two companies will work jointly on selecting and researching therapeutic targets, with Regeneron taking the lead on the subsequent development and commercialization efforts.

The collaboration is indicative of a growing trend in the pharmaceutical industry to partner in the development of gene therapies, as seen in similar alliances between other major drug companies. This venture is set to explore the potential of gene editing to address genetic diseases through precise and targeted treatment modalities.

Summary

Other news in science